Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PD-L1 >= 1% status confers therapeutic sensitivity to Ipilimumab, Nivolumab in patients with Esophageal Squamous Cell Carcinoma.
This statement is based on a regulatory approval from the Health Canada:
YERVOY, in combination with nivolumab, is indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC), with tumour cell PD-L1 expression ≥ 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.